FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200203068> ?p ?o ?g. }

• W4200203068 endingPage "e001026" @default.
• W4200203068 startingPage "e001026" @default.
• W4200203068 abstract "Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment discontinuation because of adverse events is common. Fibrotic diseases such as these can be mediated by lysophosphatidic acid (LPA), which signals via six LPA receptors (LPA1-6). Signalling via LPA1 appears to be fundamental in the pathogenesis of fibrotic diseases. BMS-986278, a second-generation LPA1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD.This phase 2, randomised, double-blind, placebo-controlled, parallel-group, international trial will include adults with IPF or PF-ILD. The trial will consist of a 42-day screening period, a 26-week placebo-controlled treatment period, an optional 26-week active-treatment extension period, and a 28-day post-treatment follow-up. Patients in both the IPF (n=240) and PF-ILD (n=120) cohorts will be randomised 1:1:1 to receive 30 mg or 60 mg BMS-986278, or placebo, administered orally two times per day for 26 weeks in the placebo-controlled treatment period. The primary endpoint is rate of change in per cent predicted forced vital capacity from baseline to week 26 in the IPF cohort.This study will be conducted in accordance with Good Clinical Practice guidelines, Declaration of Helsinki principles, and local ethical and legal requirements. Results will be reported in a peer-reviewed publication.NCT04308681." @default.
• W4200203068 created "2021-12-31" @default.
• W4200203068 creator A5000381347 @default.
• W4200203068 creator A5013400592 @default.
• W4200203068 creator A5014556433 @default.
• W4200203068 creator A5018683901 @default.
• W4200203068 creator A5026776723 @default.
• W4200203068 creator A5030667668 @default.
• W4200203068 creator A5038098413 @default.
• W4200203068 creator A5041671082 @default.
• W4200203068 creator A5043754532 @default.
• W4200203068 creator A5044159184 @default.
• W4200203068 creator A5045343022 @default.
• W4200203068 creator A5053522577 @default.
• W4200203068 creator A5058325633 @default.
• W4200203068 creator A5084744867 @default.
• W4200203068 creator A5085761603 @default.
• W4200203068 creator A5085898259 @default.
• W4200203068 creator A5087580029 @default.
• W4200203068 date "2021-12-01" @default.
• W4200203068 modified "2023-10-02" @default.
• W4200203068 title "Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)" @default.
• W4200203068 cites W1582393841 @default.
• W4200203068 cites W203879801 @default.
• W4200203068 cites W2040769700 @default.
• W4200203068 cites W2057292199 @default.
• W4200203068 cites W2063490206 @default.
• W4200203068 cites W2114232709 @default.
• W4200203068 cites W2131032222 @default.
• W4200203068 cites W2138871107 @default.
• W4200203068 cites W2147459138 @default.
• W4200203068 cites W2161787739 @default.
• W4200203068 cites W2166375403 @default.
• W4200203068 cites W2166421099 @default.
• W4200203068 cites W2168666423 @default.
• W4200203068 cites W2599075603 @default.
• W4200203068 cites W2626588662 @default.
• W4200203068 cites W2799479598 @default.
• W4200203068 cites W2823263370 @default.
• W4200203068 cites W2889197569 @default.
• W4200203068 cites W2891745120 @default.
• W4200203068 cites W2906077632 @default.
• W4200203068 cites W2964216559 @default.
• W4200203068 cites W2971111362 @default.
• W4200203068 cites W2974960379 @default.
• W4200203068 cites W2975597462 @default.
• W4200203068 cites W2990445664 @default.
• W4200203068 cites W2990890028 @default.
• W4200203068 cites W3042129721 @default.
• W4200203068 cites W3142726417 @default.
• W4200203068 cites W3145332293 @default.
• W4200203068 doi "https://doi.org/10.1136/bmjresp-2021-001026" @default.
• W4200203068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34969771" @default.
• W4200203068 hasPublicationYear "2021" @default.
• W4200203068 type Work @default.
• W4200203068 citedByCount "11" @default.
• W4200203068 countsByYear W42002030682022 @default.
• W4200203068 countsByYear W42002030682023 @default.
• W4200203068 crossrefType "journal-article" @default.
• W4200203068 hasAuthorship W4200203068A5000381347 @default.
• W4200203068 hasAuthorship W4200203068A5013400592 @default.
• W4200203068 hasAuthorship W4200203068A5014556433 @default.
• W4200203068 hasAuthorship W4200203068A5018683901 @default.
• W4200203068 hasAuthorship W4200203068A5026776723 @default.
• W4200203068 hasAuthorship W4200203068A5030667668 @default.
• W4200203068 hasAuthorship W4200203068A5038098413 @default.
• W4200203068 hasAuthorship W4200203068A5041671082 @default.
• W4200203068 hasAuthorship W4200203068A5043754532 @default.
• W4200203068 hasAuthorship W4200203068A5044159184 @default.
• W4200203068 hasAuthorship W4200203068A5045343022 @default.
• W4200203068 hasAuthorship W4200203068A5053522577 @default.
• W4200203068 hasAuthorship W4200203068A5058325633 @default.
• W4200203068 hasAuthorship W4200203068A5084744867 @default.
• W4200203068 hasAuthorship W4200203068A5085761603 @default.
• W4200203068 hasAuthorship W4200203068A5085898259 @default.
• W4200203068 hasAuthorship W4200203068A5087580029 @default.
• W4200203068 hasBestOaLocation W42002030681 @default.
• W4200203068 hasConcept C126322002 @default.
• W4200203068 hasConcept C142724271 @default.
• W4200203068 hasConcept C165637977 @default.
• W4200203068 hasConcept C203092338 @default.
• W4200203068 hasConcept C204787440 @default.
• W4200203068 hasConcept C27081682 @default.
• W4200203068 hasConcept C2777543607 @default.
• W4200203068 hasConcept C2777714996 @default.
• W4200203068 hasConcept C2778341716 @default.
• W4200203068 hasConcept C2778715236 @default.
• W4200203068 hasConcept C3018587741 @default.
• W4200203068 hasConcept C31760486 @default.
• W4200203068 hasConcept C535046627 @default.
• W4200203068 hasConcept C55520419 @default.
• W4200203068 hasConcept C71924100 @default.
• W4200203068 hasConcept C90924648 @default.
• W4200203068 hasConceptScore W4200203068C126322002 @default.
• W4200203068 hasConceptScore W4200203068C142724271 @default.
• W4200203068 hasConceptScore W4200203068C165637977 @default.
• W4200203068 hasConceptScore W4200203068C203092338 @default.
• W4200203068 hasConceptScore W4200203068C204787440 @default.

• next